Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 799-807

  Karczewska, Elzbieta ^a   Wojtas Bonior, Izabela ^a   Sito, Edward ^b   Zwoliñska Wcisło, Małgorzata ^a   Budak, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Gastroenterological Outpatient Clinic Falck Medycyna   (Poland)

Author keywords

Amoxicillin; Clarithromycin; Helicobacter pylori; Levofloxacin; Metronidazole; Resistance

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLAND;

EID: 80051513719     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70592-8     Document Type: Article

References (39)

1. Ando T, Goto Y, Maeda O, Watanabe O, Ishiguro K, Goto H: Causal role of Helicobacter pylori infection in gastric cancer. World J Gastroenterol, 2006, 12, 181-186. (Pubitemid 43336914)
2. Ba̧k-Romaniszyn L, Płaneta-Małecka I: Reasons for failure in Helicobacter pylori eradication. (Polish). Ped Wsp Gastroent Hep Żyw Dziecka, 2004, 6, 387-391.
3. Bogaerts P, Berhin C, Nizet H, Glupczynski Y: Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter, 2006, 11, 441-445. (Pubitemid 44352615)
4. Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I: Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis, 2008, 60, 409-415. (Pubitemid 351380781)
5. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Göral V et al.: The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect, 2002, 8, 388-396. (Pubitemid 34993815)
6. Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F: Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther, 2003, 17, 99-109. (Pubitemid 36140439)
7. BSAC Methods for Antimicrobial Susceptibility Testing, Version 7, 2008.
8. Chihu L, Ayala G, Mohar A, Hernández A, Herrera-Goepfert R, Fierros G, González-Márquez H, Silva J: Antimicrobial resistance and characterization of Helicobacter pylori strains isolated from Mexican adults with clinical outcome. J Chemother, 2005, 17, 270-276. (Pubitemid 40992264)
9. Cianci R, Montalto M, Pandol F, Gasbarrini G B, Cammarota G: Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol, 2006, 12, 2313-2319.
10. CLSI M100-S18, Performance Standards for Antimicrobial Susceptibility Testing, Eighteenth Informational Supplement Clinical and Laboratory Standards Institute, ISBN: 1562386530, 2008.
11. Cremonini F, Gasbarrini A, Armuzzi A, Gasbarrini G: Helicobacter pylori - related diseases. Eur J Clin Invest, 2001, 31, 431-437.
12. De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P, Russo F et al.: Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther, 2004, 19, 407-414. (Pubitemid 38297109)
13. Dunn BE, Cohen H, Blaser MJ: Helicobacter pylori. Clin Microbiol Rev, 1997, 10, 720-741. (Pubitemid 27477732)
14. Dzieniszewski J, Jarosz M; Polish Society of Gastroenterology Helicobacter pylori Working Group. Consensus of the Polish Society of Gastroenterology Helicobacter pylori Working Group on diagnostic and therapeutic approaches for the Helicobacter pylori infection (2008) (Polish). Gastroenterol Pol, 2008, 15, 323-331.
15. Dzierżanowska-Fangrat K, Rożynek E, Celiñska-Cedro D, Jarosz M, Pawłowska J, Szadkowski A, Budzyñska A et al.: Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Int J Antimicrob Agents, 2005, 26, 230-234. (Pubitemid 41219609)
16. European Helicobacter Pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997, 41, 8-13.
17. Francavilla R, Lionetti E, Castellaneta S P, Magistà A M, Boscarelli G, Piscitelli D, Amoruso A et al.: Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology, 2005, 129, 1414-1419. (Pubitemid 41597383)
18. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, Bernabucci V et al.: A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther, 2005, 22, 45-49. (Pubitemid 40943874)
19. Gerrits MM, van der Wouden EJ, Bax DA, van Zwet AA, van Vliet AHM., de Jong A, Kusters JG et al.: Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. J Med Microbiol, 2004, 53, 1123-1128. (Pubitemid 40052496)
20. Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda M de C, Mendonca S, Pedrazzoli J jr: Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol, 2003, 3, 20.
21. Graham DY: Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol, 2000, 35, 90-97.
22. Karczewska E, Wojtas I, Budak A: Occurence of Helicobacter pylori primary resistance to antibacterial drugs in Poland and in the world (Polish). Post Mikrobiol, 2009, 48, 31-41.
23. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS: Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents, 2006, 28, 6-13.
24. Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, Gottrand F et al.: Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut, 2006, 55, 1711-1716. (Pubitemid 44893567)
25. Konturek JW: Discovery by Jaworski of Helicobacter pylori and its pathogenetic role in peptic ulcer, gastritis and gastric cancer. J Physiol Pharmacol, 2003, 54, 23-41.
26. Konturek PC, Konturek SJ, Brzozowski T: Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol, 2009, 60, 3-21.
27. Łaszewicz W: Studies on Helicobacter pylori infection (Polish). Trans Humana, Białystok, 2004.
28. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R et al.: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56, 772-781. (Pubitemid 46854190)
29. Marshall BJ, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 1984, 16, 1311-1315.
30. Megraud F: Antibiotic resistance in Helicobacter pylori infection. Br Med Bull, 1998, 54, 207-216.
31. Megraud F: H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut, 2004, 53,1374-1384.
32. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C et al.: Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol, 2006, 101, 1985-1990. (Pubitemid 44337620)
33. Pieniazek P, Karczewska E, Duda A, Tracz W, Pasowicz M, Konturek SJ: Association of Helicobacter pylori infection with coronary heart disease. J Physiol Pharmacol, 1999, 50, 743-751. (Pubitemid 30090009)
34. Stassen FR, Vainas T, Bruggeman CA: Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep, 2008, 60, 85-92. (Pubitemid 351586546)
35. Tepes B: Can gastric cancer be prevented? J Physiol Pharmacol, 2009, 60, 71-77.
36. Wotherspoon AC: Gastric MALT lymphoma and Helicobacter pylori. Yale J Biol Med, 1996, 69, 61-68.
37. Ziemniak W: Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol, 2006, 57, 123-141.
38. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D: Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther, 2007, 25, 1429-1434. (Pubitemid 46848887)
39. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V et al.: High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther, 2003, 17, 719-726. (Pubitemid 36418897)